Hervé Raspaldo1. 1. Palais Armenonville, Rond Point Duboys d'Angers, Cannes, France. raspaldo@clinic.com.fr
Abstract
INTRODUCTION: Many signs of aging are due to the loss of subcutaneous fat. Dermal fillers are non-surgical cosmetic treatments used to restore facial volume. Voluma is a new hyaluronic acid sub-dermal facial filler. The objective of this study was to assess its effectiveness in maintaining increased volume for up to 18 months post-treatment and its safety. METHODS: Retrospective record analysis was made for 102 patients (93 females, nine males; mean age: 51.27 years) who received Voluma injected into the midface. All patients were assessed at baseline and at 1 month and 6-18 months post-injection. RESULTS: Investigator Global Aesthetic Improvement assessment after 1 month and 6-18 months showed that most patients were 'much' or 'very much' improved. Investigator volume loss assessment confirmed that most patients were either stage 1 or 2 (normal or slight ptosis) 1 month post-treatment, which was maintained at 6-18 months. Patient efficacy assessment was 'very good' or 'good' in most cases. CONCLUSIONS: Voluma provides aesthetic improvements according to investigator and patient assessment for up to 18 months post-treatment. Combination treatment comprising facial fillers and botulinum neurotoxin can enhance treatment benefits. Further methodologically rigorous studies are required to establish the performance of Voluma alone and in combination.
INTRODUCTION: Many signs of aging are due to the loss of subcutaneous fat. Dermal fillers are non-surgical cosmetic treatments used to restore facial volume. Voluma is a new hyaluronic acid sub-dermal facial filler. The objective of this study was to assess its effectiveness in maintaining increased volume for up to 18 months post-treatment and its safety. METHODS: Retrospective record analysis was made for 102 patients (93 females, nine males; mean age: 51.27 years) who received Voluma injected into the midface. All patients were assessed at baseline and at 1 month and 6-18 months post-injection. RESULTS: Investigator Global Aesthetic Improvement assessment after 1 month and 6-18 months showed that most patients were 'much' or 'very much' improved. Investigator volume loss assessment confirmed that most patients were either stage 1 or 2 (normal or slight ptosis) 1 month post-treatment, which was maintained at 6-18 months. Patient efficacy assessment was 'very good' or 'good' in most cases. CONCLUSIONS: Voluma provides aesthetic improvements according to investigator and patient assessment for up to 18 months post-treatment. Combination treatment comprising facial fillers and botulinum neurotoxin can enhance treatment benefits. Further methodologically rigorous studies are required to establish the performance of Voluma alone and in combination.
Authors: Greg J Goodman; Phillip Bekhor; Michael Rich; Robert H Rosen; Michael B Halstead; John D Rogers Journal: Clin Cosmet Investig Dermatol Date: 2011-12-20
Authors: Daisy Kopera; Michael Palatin; Rolf Bartsch; Katrin Bartsch; Maria O'Rourke; Sonja Höller; Renate R Baumgartner; Martin Prinz Journal: Biomed Res Int Date: 2015-03-03 Impact factor: 3.411
Authors: Channy Muhn; Nathan Rosen; Nowell Solish; Vince Bertucci; Mark Lupin; Alain Dansereau; Fred Weksberg; B Kent Remington; Arthur Swift Journal: Clin Cosmet Investig Dermatol Date: 2012-10-05
Authors: Peter Callan; Greg J Goodman; Ian Carlisle; Steven Liew; Peter Muzikants; Terrence Scamp; Michael B Halstead; John D Rogers Journal: Clin Cosmet Investig Dermatol Date: 2013-03-20